Capecitabine Tablet, Film Coated
Product Images NDC 16729-072

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 16729-072). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (Capecitabine 150 Label)

Principal Display Panel (Capecitabine 150 Label)
This is the label of Capcitabine USP 150mg tablets containing NG 16726-072-12. Capecitabine tablets should not be cut or crushed. Recommended storage temperature is 25°C and should be kept tightly closed in a clean area. Dosage recommendations can be found on the accompanying insert. This medication is a cytotoxic agent manufactured by Intas Pharmaceuticals Limited in Ahmadabad, India for Accord Healthcare Inc. in Durham, NC.*
FDA Label Image

Principal Display Panel (Capecitabine 500 Label)

Principal Display Panel (Capecitabine 500 Label)
Each tablet contains 500mg Capecitabine USP – a cytotoxic agent. Capecitabine tablets shouldn't be crushed or cut and should be stored in tightly enclosed USP-compliant containers at 15° 10 30°C (50° 1o 86°F). The pharmaceutical product has been manufactured by Intas Pharmaceuticals Limited in India and is dispensed by Accord Healthcare, Inc., based in Durham, NC, 27703. For precise dosage and prescription information, read the included insert. NDC is 16729-073-29.*
FDA Label Image

Figure 1 (Capecitabine Fig1)

FDA Label Image

Figure 2 (Capecitabine Fig2)

FDA Label Image

Figure 3 (Capecitabine Fig3)

Figure 3 (Capecitabine Fig3)
This text appears to be a chart or table with a list of estimated probabilities ranging from 0.0 to 10, and refers to the use of two cancer treatments, "5-FU + Leucovorin (Mayo Regimen)" and "Capecitabine 1250 (mg/sqm e daily)", administered intermittently over a period of days. The numbers 600, 900, 1200, and 1500 are likely time intervals.*
FDA Label Image

Figure 4 (Capecitabine Fig4)

FDA Label Image

Figure 5 (Capecitabine Fig5)

Figure 5 (Capecitabine Fig5)
This text appears to be a list of different chemotherapy drugs and their corresponding dosages, but it is not clear whether it is a complete list or what medical condition they are being used to treat.*
FDA Label Image

Chemical Structure (Capecitabine Met Path)

FDA Label Image

Chemical Structure (Capecitabine Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.